Claudio Liguori1, Andrea Romigi1, Marzia Nuccetelli2, Silvana Zannino1, Giuseppe Sancesario3, Alessandro Martorana3, Maria Albanese1, Nicola Biagio Mercuri4, Francesca Izzi1, Sergio Bernardini2, Alessandra Nitti1, Giulia M Sancesario5, Francesco Sica6, Maria G Marciani6, Fabio Placidi1. 1. Neurophysiopathology Unit, Sleep Medicine Centre, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. 2. Department of Clinical Biochemistry and Molecular Biology, University of Rome Tor Vergata, Rome, Italy. 3. Neurology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy4Neuroscience Unit, Fondazione Santa Lucia, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy. 4. Neurophysiopathology Unit, Sleep Medicine Centre, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy4Neuroscience Unit, Fondazione Santa Lucia, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy. 5. Neuroscience Unit, Fondazione Santa Lucia, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy. 6. Neurology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Abstract
IMPORTANCE: Nocturnal sleep disruption develops in Alzheimer disease (AD) owing to the derangement of the sleep-wake cycle regulation pathways. Orexin contributes to the regulation of the sleep-wake cycle by increasing arousal levels and maintaining wakefulness. OBJECTIVES: To study cerebrospinal fluid levels of orexin in patients with AD, to evaluate the relationship of orexin cerebrospinal fluid levels with the degree of dementia and the cerebrospinal fluid AD biomarkers (tau proteins and β-amyloid 1-42), and to analyze potentially related sleep architecture changes measured by polysomnography. DESIGN, SETTING, AND PARTICIPANTS: We conducted a case-control study from August 1, 2012, through May 31, 2013. We included 48 drug-naive AD patients referred to the Neurological Clinic of the University Hospital of Rome Tor Vergata. Based on the Mini-Mental State Examination score, 21 patients were included in mild AD group (score, ≥21), whereas 27 were included in the moderate to severe AD group (score, <21). The control group consisted of 29 nondemented participants of similar age and sex. EXPOSURE: Laboratory assessment of cerebrospinal fluid levels of orexin, tau proteins, and β-amyloid 1-42 and polysomnographic assessment of sleep variables. MAIN OUTCOMES AND MEASURES: Levels of orexin, tau proteins, and β-amyloid 1-42; macrostructural variables of nocturnal sleep (total sleep time, sleep efficiency, sleep onset and rapid eye movement [REM] sleep latencies, non-REM and REM sleep stages, and wakefulness after sleep onset); and Mini-Mental State Examination scores. RESULTS: Patients with moderate to severe AD presented with higher mean (SD) orexin levels compared with controls (154.36 [28.16] vs 131.03 [26.55]; P < .01) and with more impaired nocturnal sleep with respect to controls and patients with mild AD. On the other hand, in the global AD group, orexin levels were positively correlated with total tau protein levels (r = 0.32; P = .03) and strictly related to sleep impairment. Finally, cognitive impairment, as measured by the Mini-Mental State Examination, was correlated with sleep structure deterioration. CONCLUSIONS AND RELEVANCE: Our results demonstrate that, in AD, increased cerebrospinal fluid orexin levels are related to a parallel sleep deterioration, which appears to be associated with cognitive decline. Therefore, the orexinergic system seems to be dysregulated in AD, and its output and function appear to be overexpressed along the progression of the neurodegenerative process. This overexpression may result from an imbalance of the neurotransmitter networks regulating the wake-sleep cycle toward the orexinergic system promoting wakefulness.
IMPORTANCE: Nocturnal sleep disruption develops in Alzheimer disease (AD) owing to the derangement of the sleep-wake cycle regulation pathways. Orexin contributes to the regulation of the sleep-wake cycle by increasing arousal levels and maintaining wakefulness. OBJECTIVES: To study cerebrospinal fluid levels of orexin in patients with AD, to evaluate the relationship of orexin cerebrospinal fluid levels with the degree of dementia and the cerebrospinal fluid AD biomarkers (tau proteins and β-amyloid 1-42), and to analyze potentially related sleep architecture changes measured by polysomnography. DESIGN, SETTING, AND PARTICIPANTS: We conducted a case-control study from August 1, 2012, through May 31, 2013. We included 48 drug-naive ADpatients referred to the Neurological Clinic of the University Hospital of Rome Tor Vergata. Based on the Mini-Mental State Examination score, 21 patients were included in mild AD group (score, ≥21), whereas 27 were included in the moderate to severe AD group (score, <21). The control group consisted of 29 nondemented participants of similar age and sex. EXPOSURE: Laboratory assessment of cerebrospinal fluid levels of orexin, tau proteins, and β-amyloid 1-42 and polysomnographic assessment of sleep variables. MAIN OUTCOMES AND MEASURES: Levels of orexin, tau proteins, and β-amyloid 1-42; macrostructural variables of nocturnal sleep (total sleep time, sleep efficiency, sleep onset and rapid eye movement [REM] sleep latencies, non-REM and REM sleep stages, and wakefulness after sleep onset); and Mini-Mental State Examination scores. RESULTS:Patients with moderate to severe AD presented with higher mean (SD) orexin levels compared with controls (154.36 [28.16] vs 131.03 [26.55]; P < .01) and with more impaired nocturnal sleep with respect to controls and patients with mild AD. On the other hand, in the global AD group, orexin levels were positively correlated with total tau protein levels (r = 0.32; P = .03) and strictly related to sleep impairment. Finally, cognitive impairment, as measured by the Mini-Mental State Examination, was correlated with sleep structure deterioration. CONCLUSIONS AND RELEVANCE: Our results demonstrate that, in AD, increased cerebrospinal fluid orexin levels are related to a parallel sleep deterioration, which appears to be associated with cognitive decline. Therefore, the orexinergic system seems to be dysregulated in AD, and its output and function appear to be overexpressed along the progression of the neurodegenerative process. This overexpression may result from an imbalance of the neurotransmitter networks regulating the wake-sleep cycle toward the orexinergic system promoting wakefulness.
Authors: Saranya Sundaram; Rachel L Hughes; Eric Peterson; Eva M Müller-Oehring; Helen M Brontë-Stewart; Kathleen L Poston; Afik Faerman; Chloe Bhowmick; Tilman Schulte Journal: Neurosci Biobehav Rev Date: 2019-05-24 Impact factor: 8.989
Authors: Jason R Gerstner; Olivia Lenz; William M Vanderheyden; May T Chan; Cory Pfeiffenberger; Allan I Pack Journal: J Neurosci Res Date: 2016-06-19 Impact factor: 4.164
Authors: Breton M Asken; Molly J Sullan; Aliyah R Snyder; Zachary M Houck; Vaughn E Bryant; Loren P Hizel; Molly E McLaren; Duane E Dede; Michael S Jaffee; Steven T DeKosky; Russell M Bauer Journal: Neuropsychol Rev Date: 2016-08-25 Impact factor: 7.444
Authors: Ricardo S Osorio; Emma L Ducca; Margaret E Wohlleber; Emily B Tanzi; Tyler Gumb; Akosua Twumasi; Samuel Tweardy; Clifton Lewis; Esther Fischer; Viachaslau Koushyk; Maria Cuartero-Toledo; Mohammed O Sheikh; Elizabeth Pirraglia; Henrik Zetterberg; Kaj Blennow; Shou-En Lu; Lisa Mosconi; Lidia Glodzik; Sonja Schuetz; Andrew W Varga; Indu Ayappa; David M Rapoport; Mony J de Leon Journal: Sleep Date: 2016-06-01 Impact factor: 5.849